Virtual Reality VAlidation Tool for Cognitive Rehabilitation, Oriented Project for People With Psychosocial Disabilieties

Sponsor
University of Cagliari (Other)
Overall Status
Recruiting
CT.gov ID
NCT05070065
Collaborator
(none)
60
1
2
11.7
5.1

Study Details

Study Description

Brief Summary

Randomized controlled open-label cross-over clinical feasibility study with waiting list, 60 people will be recruited from the Consultation and Psychosomatic Psychiatry Center of the University Hospital of Cagliari (San Giovanni di Dio Civil Hospital) with a diagnosis of mental disorder. The investigators propose a VR intervention of 3 months with 2 weekly session of CEREBRUM (cognitive remedy intervention with virtual reality) first to the group A and then to the group B.

Condition or Disease Intervention/Treatment Phase
  • Device: Cognitive remedy intervention with virtual reality (CEREBRUM)
N/A

Detailed Description

Background: Cognitive remedial interventions have been found to be effective in the treatment of various psycho-social disorders. The use of Virtual reality as a rehabilitation tool has been showing various scientific evidences in recent years like in cardiovascular, neurological and musculoskeletal rehabilitation. In mental health evidence they seem to be concentrated in the rehabilitation of social cognition in people with schizophrenia diagnosis and psychotherapy. The aim of this study is to evaluate the feasibility and the effectiveness of the first Cognitive Remedial toll in Virtual Reality (CEREBRUM) for people that has experienced in mental health.

Methods: Randomized controlled open-label cross-over clinical feasibility study with waiting list, 60 people will be recruited from the Consultation and Psychosomatic Psychiatry Center of the University Hospital of Cagliari (San Giovanni di Dio Civil Hospital) with a diagnosis of mental disorder. The investigators propose a intervention of 3 months with 2 weekly session of CEREBRUM first to the group A and then to the group B

Study Design

Study Type:
Interventional
Anticipated Enrollment :
60 participants
Allocation:
Randomized
Intervention Model:
Crossover Assignment
Intervention Model Description:
Randomized controlled open-label cross-over clinical feasibility study with waiting listRandomized controlled open-label cross-over clinical feasibility study with waiting list
Masking:
Single (Participant)
Masking Description:
people with psychosocial disabilities
Primary Purpose:
Treatment
Official Title:
VIVA-CORE! Virtual Reality VAlidation Tool for Cognitive Rehabilitation, a REcovery Oriented Project for People With Psychosocial Disabilieties: Protocol of Randomize Clinical Trial
Actual Study Start Date :
Nov 10, 2021
Anticipated Primary Completion Date :
May 1, 2022
Anticipated Study Completion Date :
Nov 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: virtual reality

The experimental group A receives the cognitive remedy intervention with virtual reality (CEREBRUM)

Device: Cognitive remedy intervention with virtual reality (CEREBRUM)
Cognitive Remedial method Virtual Reality (CEREBRUM)

Other: waiting list

waiting list

Device: Cognitive remedy intervention with virtual reality (CEREBRUM)
Cognitive Remedial method Virtual Reality (CEREBRUM)

Outcome Measures

Primary Outcome Measures

  1. Memory [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Rey's Figure Test Word's Figure Test Digit Span Forward and Backward Test Test of the Tale

  2. Monitoring Side effects of Virtual Reality [During the first VR session - At 1 month (after 8 sessions) - T1 (at 3 months from baseline)]

    Questionnaire (Qualitative)

  3. Attention [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Matrix Test Digit Symbol Substitution Test

  4. Executive functions [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Trial Making Test Verbal Phonological and Semantic Fluency Test Cognitive Estimation Test - CET Stroop Test Frontal Assessment Battery - FAB

Secondary Outcome Measures

  1. Quality of Life [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Short Form Healthy Survey Questionnaire - SF-12

  2. Alexithymia [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Toronto Alexithymia Scale - TAS-20

  3. Anxiety [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Self Anxiety Rating Scale - SAS

  4. Depression [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    The Patient Health Questionnaire - PHQ-9

  5. Biological Rythms [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Biological Rythms Interview of Assesment in Neuropsychiatry - BRIAN

  6. General and social functioning [All measure at: T0 (base line) -T1 (at 3 months from baseline) -T2 (at 6 months from baseline) -T3 (at 12 months from baseline)]

    Health of the Nation Outcome Scales - HoNOS

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 75 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Age from 18 to 75;

  • Diagnosis of psychosis and / or mood disorder according to DSM-IV (American Psychiatric Association, 2000).

  • both sexes;

  • users who sign the informed consent;

  • users under protection for which the informed consent is signed by the guardian

Exclusion Criteria:
  • The non-satisfaction of the inclusion criteria;

  • The diagnosis of epilepsy or serious eye diseases, due to the risk associated with the excessive stimulation of virtual reality

Contacts and Locations

Locations

Site City State Country Postal Code
1 P.O. San Giovanni di Dio, AOU Cagliari Cagliari Italy 09100

Sponsors and Collaborators

  • University of Cagliari

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Mauro Giovanni Carta, Professor, University of Cagliari
ClinicalTrials.gov Identifier:
NCT05070065
Other Study ID Numbers:
  • Prot. PG/2020/7577
First Posted:
Oct 6, 2021
Last Update Posted:
Dec 23, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mauro Giovanni Carta, Professor, University of Cagliari
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 23, 2021